Genelux Corporation
NASDAQ:GNLXBiotechnology
+$0.08 today
- Market cap
- $107.66M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
Volume 0.80M
Average 0.19M
GNLX Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Genelux CorporationNASDAQ: GNLX
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital growth accelerates
Q1 FY2026 change in working capital of $1.06M rose 101.5% year over year, ahead of the -118.2% change in trailing-twelve-month change in working capital. Sequentially, it rose 4.4% from the prior quarter. Over 3 fiscal years it compounded at -14.8% a year.
Context
- Change in working capital amounted to 13075.0% of revenue in FY2025, up 3687.5 pp from a year earlier.
- Change in working capital increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +101.5% holds above the trailing-twelve-month pace of -118.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (1.05M) USD
- Year-over-year change
- -239.3%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.05M) | -239.3% |
| FY2024 | 2024-12-31 | 751K | +122.9% |
| FY2023 | 2023-12-31 | (3.28M) | -94.0% |
| FY2022 | 2022-12-31 | (1.69M) | -141.4% |
| FY2021 | 2021-12-31 | 4.08M | — |
Change in Working Capital vs competitors
How GNLX compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -118.2% is the 4th highest of 9, against a peer median of -124.4%.
- Change in working capital amounts to 6400.0% of revenue for GNLX, versus a peer median of 130.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $20.45M USD | -475.2% | — | — |
| LTM Mar 2026 | $11.31M USD | -122.0% | +93.9% | 16.6% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $10.9M USD | -374.2% | +68.3% | — |
| LTM Mar 2026 | $5.6M USD | — | — | 607.2% | |
| LTM Dec 2025 | CHF 4.65M CHF | -104.3% | -8.4% | 130.0% | |
| LTM Dec 2025 | $2.29M USD | — | — | — | |
| LTM Mar 2026 | $1.42M USD | -84.9% | -50.6% | 4593.5% | |
| LTM Mar 2026 | $1.22M USD | -126.7% | +14.6% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $512K USD | -118.2% | -14.8% | 6400.0% |
| LTM Mar 2026 | $447K USD | +120.2% | +213.8% | — | |
| LTM Mar 2026 | $299.66K USD | -178.4% | +10.9% | 59.9% | |
| Peer median (excluding GNLX) | — | -124.4% | +14.6% | 130.0% | |
Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.38M) | (5.21M) | (28.3M) | (29.87M) | (32.15M) |
| Depreciation & Amortization | 895K | 968K | 1.02M | 903K | 244K |
| Deferred Income Tax | 348K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.27M | 2.42M | 5.2M | 6.07M | 5.87M |
| Change in Working Capital | 4.08M | (1.69M) | (3.28M) | 751K | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 754K | 2.31M | (2.36M) | 2.16M | (1.21M) |
| Other Working Capital | 3.33M | (4M) | (923K) | (1.41M) | 167K |
| Other Non-Cash Items | 196K | (56K) | 5.08M | 917K | 1.81M |
| Operating Cash Flow | (6.59M) | (3.57M) | (20.28M) | (21.23M) | (25.27M) |
| Capital Expenditures | 0 | (49K) | (1.03M) | (381K) | (1.1M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (13.7M) | (29M) | (18.26M) |
| Sales of Investments | 0 | 0 | 0 | 21.25M | 31.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (49K) | (14.72M) | (8.13M) | 12.14M |
| Debt Repayment | (558K) | 970K | 215K | 0 | 0 |
| Common Stock Issued | 143K | 120K | 39.65M | 27.82M | 9.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 145K | (1.45M) | 4.16M | 688K | 0 |
| Financing Cash Flow | (270K) | (478K) | 44.02M | 28.51M | 9.9M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.86M) | (4.1M) | 9.02M | (853K) | (3.23M) |
| Free Cash Flow | (6.59M) | (3.62M) | (21.3M) | (21.61M) | (26.37M) |
Genelux Corporation
NASDAQ:GNLX
Intrinsic Alpha fair value
Locked
Current Price
$2.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.